

**Report by the Comissió d'Avaluació Econòmica i Impacte Pressupostari, CAEIP (Economic Evaluation and Budget Impact Commission), of Catsalut, about the corticoids inhaled alone or associates with adrenergic agonist beta-2 of prolonged action in the treatment of the chronic asthma in adults and children over 12 years commercialized in Spain**

The asthma is a problem of health with a high prevalence and with important implications in the quality of life of the patients.

In the pharmatherapeutic field, there are multiple alternatives. Due to the prevalence of the pathology and its priority in health, it was considered indispensable to revise the pharmaceutical offer applying criteria of cost-effectiveness. Because of that, from the CAEIP the realization of the systematic Revision of economic evaluations was in charge of the corticoids inhaled alone or associates with adrenergic agonist beta-2 of action prolonged in the treatment of the asthma chronic in adults and children over 12 years commercialized in Spain.

Considering the results of the systematic revision of economic evaluations of the inhaled corticoids, alone or associates with agonists adrenergic beta-2 in the treatment of the chronic asthma in adults and in children over 12 years<sup>1</sup>, another evidence<sup>2</sup> available and the appraisals of the members of the CAEIP, the CAEIP recommends the following measures for an efficient selection of medicines for the treatment of the chronic asthma in adults and children over 12 years:

- In monotherapy with inhaled corticoids, it recommends the/those of minor price per day of treatment since the efficacy is similar among the different disposable options.
- In those patients who do not respond to corticoids to high doses, it recommends to make the therapeutic change to a suitable combination of inhaled corticoids and agonists beta-2 of prolonged action.

---

<sup>1</sup> Systematic revision of economic evaluations about inhaled corticoids, alone or associates with agonists adrenergic beta-2 of action prolonged in the treatment of the chronic asthma in adults and in children over 12 years. Juan Oliva, Marta Trapero y M<sup>a</sup> Dolores Fraga. 200

<sup>2</sup> Gema 2009. Spanish guide for asthma management. Madrid 2009

**Note on the review:** the validity of the statments in this report is subject to the possible variations in the effectiveness and/or cost shown by the clinical evidence and the estudies made available after the date of publication of his report. The CAEIP shall, at least every 2 years, review this report according to the emergence of newly available evidence.

- Among the combinations of active principles of inhaled corticoids and available beta-2 of prolonged action from the perspective of cost-effectiveness, there is not enough evidence for recommending an option towards the other one.
- That the changes of medication are subordinated to patients badly controlled or to those patients where the change of treatment assures a good inhalatory technique and fulfillment on the part of the patients.

These recommendations do not have to imply discarding the selection of the therapeutic alternative that, according to the clinical criterion, one generates more effectiveness of the treatment in determinate patients.

Barcelona, 16 September 2010

**Note on the review:** the validity of the statements in this report is subject to the possible variations in the effectiveness and/or cost shown by the clinical evidence and the studies made available after the date of publication of his report. The CAEIP shall, at least every 2 years, review this report according to the emergence of newly available evidence.